CONFERENCE UPDATE: ASH 2020

Updated Guidelines for the Management of Venous Thromboembolism (VTE)

HEMATOLOGY
27 Feb 2021

A multidisciplinary guideline panel from the American Society of Hematology (ASH), with support from the McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre, has drafted a list of 28 recommendations for the initial venous thromboembolism (VTE) management, primary treatment, secondary prevention and the treatment of recurrent VTE events.1

Differences between the ASH and 4 other recent guidelines concerning the management of patients with VTE include the consistent use of systematic reviews and evidence-to-decision frameworks as well as the use of marker states to estimate the relative importance of key treatment outcomes to patients.1

Strong and new recommendations are highlighted in Table 1 with the list of 28 recommendations summarized in Table 2.

Get access to our exclusive articles.
Related Articles

Updates to the ASH guidelines on VTE: Thrombophilia testing and anticoagulation in COVID-19 patients

Both thrombophilia (acquired or hereditary) and coronavirus disease 2019 (COVID-19) are associated with an increased risk of venous thromboembolism (VTE).1,2 ASH thus developed guidelines that aimed to provide evidence-based recommendations to support decision-making about thrombophilia testing and

HEMATOLOGY
28 Feb 2024

ASH guidelines and the implementation strategies for the prevention of cancer-associated VTE

In the ASH Annual Meeting& Exposition 2022, Dr. Marc Carrier from the University of Ottawa, Canada, and Dr. Katy Toale from the Anderson Cancer Center, the United States, presented the implementation of risk assessment model and consideration for thromboprophylaxis in ambulatory cancer patients who
HEMATOLOGY
09 Mar 2023

Balancing the risk and benefit of anticoagulation in cancer patients with high bleeding risk

Bleeding is a common problem estimated to occur in 6-10% of advanced cancer patients.1 Bleeding can be caused by the cancer itself, be related to radiation or chemotherapy treatment, or exacerbated by immunotherapies and anticoagulants.2 Patients may also be predisposed to bleeding due to thrombocyt
ONCOLOGY
27 Dec 2020

ASCO released updated guidelines for the prophylaxis and treatment of venous thromboembolism in patients with cancer

Venous thromboembolism (VTE), which includes deep-vein thrombosis and pulmonary embolism, is an important cause of morbidity and mortality amongst patients with cancer.1 The American Society of Clinical Oncology (ASCO) first

ONCOLOGY
30 Oct 2019

Approval of brentuximab vedotin for newly diagnosed peripheral T-cell lymphoma (including systemic anaplastic large cell lymphoma)

Despite intensive front-line therapy, peripheral T-cell lymphoma (PTCL) has typically poor clinical outcomes and low complete remission rates.1 Brentuximab vedotin is an antibody-drug conjugate, and with its use in combination

HEMATOLOGY
28 Feb 2019